Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
- PMID: 33157162
- DOI: 10.1016/j.bbcan.2020.188461
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Abstract
Pancreatic cancer is a lethal disease with limited opportunity for resectable surgery as the first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma and cellular genetic or epigenetic alterations of pancreatic cancer impose physical and biological barriers to effective therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Here, we review the current therapeutic options for pancreatic cancer, and underlying mechanisms and potential reversal of therapeutic resistance, a hallmark of this deadly disease.
Keywords: Chemotherapy; Immunotherapy; Pancreatic cancer; Radiotherapy; Therapeutic resistance.
Copyright © 2020. Published by Elsevier B.V.
Similar articles
-
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.Drug Resist Updat. 2024 Nov;77:101146. doi: 10.1016/j.drup.2024.101146. Epub 2024 Aug 30. Drug Resist Updat. 2024. PMID: 39243602 Review.
-
The biological underpinnings of therapeutic resistance in pancreatic cancer.Genes Dev. 2021 Jul 1;35(13-14):940-962. doi: 10.1101/gad.348523.121. Epub 2021 Jun 11. Genes Dev. 2021. PMID: 34117095 Free PMC article. Review.
-
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16. Expert Opin Investig Drugs. 2019. PMID: 30539678 Review.
-
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Drug Resist Updat. 2017. PMID: 28867243 Review.
-
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.Lancet Oncol. 2020 Mar;21(3):e135-e145. doi: 10.1016/S1470-2045(19)30795-8. Lancet Oncol. 2020. PMID: 32135117 Free PMC article. Review.
Cited by
-
The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment.Front Oncol. 2022 Jun 7;12:904327. doi: 10.3389/fonc.2022.904327. eCollection 2022. Front Oncol. 2022. PMID: 35747788 Free PMC article.
-
Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target.Molecules. 2021 Aug 11;26(16):4849. doi: 10.3390/molecules26164849. Molecules. 2021. PMID: 34443437 Free PMC article. Review.
-
MicroRNA-485-5p targets keratin17 to regulate pancreatic cancer cell proliferation and invasion via the FAK / SRC / ERK pathway.J Cancer. 2024 Feb 17;15(7):2033-2044. doi: 10.7150/jca.90689. eCollection 2024. J Cancer. 2024. PMID: 38434984 Free PMC article.
-
Circ_103809 Aggravates the Malignant Phenotype of Pancreatic Cancer Through Modulating miR-197-3p/TSPAN3 Axis.Mol Biotechnol. 2024 Sep;66(9):2455-2466. doi: 10.1007/s12033-023-00874-0. Epub 2023 Sep 23. Mol Biotechnol. 2024. PMID: 37740818
-
Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer.iScience. 2024 Dec 16;28(1):111612. doi: 10.1016/j.isci.2024.111612. eCollection 2025 Jan 17. iScience. 2024. PMID: 39834857 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical